This Phase I study of HMPL-306, an oral, small-molecule dual inhibitor of mutated isocitrate dehydrogenase 1/2 (mIDH1/2) investigated the safety and preliminary efficacy of HMPL-306 for the treatment of patients with relapsed/refractory acute myeloid leukemia with mIDH1/2.
[Med]